Several cannabinoids (cannabidivarin (CBDV), cannabigerol (CBG), cannabidiol (CBD), cannabinol (CBN) and cannabichromene (CBC)) and ethanol hemp extract are being used in primary human hepatocytes (PHH), Caenorhabditis elegans (C. elegans) and in vitro buccal membrane absorption models to elucidate their potential toxicological mechanisms, evaluate their oromucosal absorption, and to identify their metabolites. William’s E medium, C. elegans habitation medium (CeHM), and HEPES-buffered hanks' balanced salt solution (HHBSS) are matrices used with these predictive test systems. Therefore, we developed and validated a sensitive fit-for-purpose ultra-high performance liquid chromatography-electrospray-tandem mass spectrometry (UHPLC-ESI-MS/MS) method for the quantitation of CBDV, CBG, CBD, CBN, and CBC in extracellular matrices used with these models for the first time. The separation of the analytes was performed on a Waters ACQUITY UPLC BEH C18 column (130 Å, 1.7 μm, 2.1 × 100 mm) protected with a Waters ACQUITY UPLC BEH C18 guard column (130 Å, 1.7 μm, 2.1 × 5 mm). Positive electrospray ionization and multiple reaction monitoring (MRM) modes were used. Under the developed experimental conditions, good linearities were obtained over the concentration range of 0.025–40 µg/ml with coefficients of determination (R2) varying from 0.9953 to 0.9998. The intra-day precisions were between 0.5 and 9.6% with accuracies within ± 16.7%, and the inter-day precisions ranged from 0.6 to 13.1 % with accuracies within ± 13.7%. The method recoveries were between 85.8 and 105.1%. In addition, time-consuming sample preparation was avoided by applying a simple and efficient extraction procedure, which meets the need for potential large-scale routine analysis. The described method was successfully applied to quantitate the analytes in samples produced with different models as well as in ethanolic hemp extract.